Journal
THORACIC SURGERY CLINICS
Volume 24, Issue 3, Pages 333-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.thorsurg.2014.04.005
Keywords
Bone marrow; Bronchopulmonary; Carcinoid; Gastroenteropancreatic neuroendocrine tumor; Hepatic neuroendocrine metastasis; Peptide receptor radionuclide therapy; PART; Renal toxicity
Categories
Ask authors/readers for more resources
Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable beta-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane. After almost 2 decades of experience, PRRT, with either Y-90-octreotide or Lu-177-octreotate, has established itself to be an efficient and effective therapeutic modality. As a treatment, it is relatively safe up to the known thresholds of absorbed and bio-effective isotope dosages and the renal and hematological toxicity profiles are acceptable if adequate protective measures are undertaken.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available